cep-11981
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2007 (NCT00875264)
Timeline
Indications
Mechanism of action
- Tyrosine-protein kinase TIE-2INHIBITOR
TEK inhibitor
Vascular endothelial growth factor receptor inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)Cn1c2ccc(Nc3ncccn3)cc2c2c3c(c4c(c21)CCc1nn(C)cc1-4)C(=O)NC3- Mol. weight
- 477.57 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2010872 ↗
Also known as
- 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4h-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one
- cep-11981
- cep-11981
- cep-11981
- cep-11981
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04159896 | Phase 2 | Oct 31, 2019 | National Cancer Institute (NCI), Wayne State University |
| NCT00875264 | Phase 1 | Sep 1, 2007 | Cephalon |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cephalon | For profit | 1 | 1 | 1 | 2007 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2019 |
| Wayne State University | Academic/Hospital | 1 | 1 | 1 | 2019 |
3 organizations
Page 1 / 1